Alnylam, Sarepta jump into Covid-19 game, as pandemic rekindles antiviral hopes of RNA-targeting technology
The idea had been there from the beginning. Scientists, studying plants and worms at the turn of the 21st century, discovered a mechanism cells used to cut up the RNA of invading viruses. Why not rejig the mechanism, called RNA interference (RNAi), to spear the viruses that attacked humans?
“Even way, way at the beginning, it was one of the areas of interest,” John Maraganore, CEO of RNAi biotech Alnylam, told Endpoints News.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 107,000+ biopharma pros reading Endpoints daily — and it's free.